Literature DB >> 7658434

Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.

J S Ward1, L Merritt, D O Calligaro, F P Bymaster, H E Shannon, B D Sawyer, C H Mitch, J B Deeter, S C Peters, M J Sheardown, P H Olesen, M D Swedberg, P Sauerberg.   

Abstract

In an attempt to improve upon the M1 agonist activity of the selective M1 agonist xanomeline and related compounds, the M1 muscarinic efficacies and potencies of 3- and 6-substituted pyrazinylazacycles were varied by changing both the 3- and 6-substituents as well as the azacycle. Significant improvements in efficacy and potency over the previously prepared [3-(hexyloxy)pyrazinyl]tetrahydropyridine 19 were obtained with the [3-(hexyloxy)pyrazinyl]-quinuclidine 5i. The M1 activity of 5i showed some enantioselectivity with (S)-5i being ca. 4-fold more potent than (R)-5i. Like 19 and xanomeline, 5i was a functionally selective M1 agonist that showed greater functional selectivity than widely studied pyrazinylquinuclidine 5n (L-689,660). The improved functional selectivity of 5i over 5n could be attributed to the additional binding interactions between the hexyloxy side chain of 5i and the M1 receptor that are not available to 5n. Although 5i may show M1 functional selectivity comparable to xanomeliine, 5i is a less efficacious and potent M1 agonist than xanomeline.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658434     DOI: 10.1021/jm00018a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

3.  A simple method for quantifying functional selectivity and agonist bias.

Authors:  Terry Kenakin; Christian Watson; Vanessa Muniz-Medina; Arthur Christopoulos; Steven Novick
Journal:  ACS Chem Neurosci       Date:  2011-12-20       Impact factor: 4.418

Review 4.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07

5.  Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.

Authors:  Christopher N Davis; Stefania Risso Bradley; Hans H Schiffer; Mikael Friberg; Kristian Koch; Bo-Ragnar Tolf; Douglas W Bonhaus; Jelveh Lameh
Journal:  BMC Pharmacol       Date:  2009-12-02

Review 6.  The potential for selective pharmacological therapies through biased receptor signaling.

Authors:  Terry Kenakin
Journal:  BMC Pharmacol Toxicol       Date:  2012-08-13       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.